The commonest cause of chronic heat failure in China is ischemic heart disease, followed by hypertension and valvular heart disease. Echocardiography is essential in establishing a diagnosis as well as helping to identify a cause and to monitor progress. Management includes nonpharmacological as well as pharmacological treatment, and self-care with careful monitoring of salt and fluid intake as well as regular weight measurement. Care planning and team-based care are essential in managing patients with chronic heart failure, who often have concurrent multimorbidity and are receiving polypharmacy.
Introduction
In the past 3 decades there has been a dramatic improvement globally in the management of car- Patients with cardiac failure have frequent hospital admissions, with average lengths of stay of 7-10 days. This is costly, and there is evidence that shorter stays in observation 4 ORIGINAL RESEARCH units are possible [2] . End-stage heart failure requires palliative care, which may lead to further hospitalization. The role of the GP in managing heart failure is therefore critical, and includes prevention by careful monitoring of early signs and adherence to medication, early intervention with appropriate medication, and active engagement with other specialists involved with the care team while at all times engaging with the family and caregivers to keep the patient at home and active for as long as possible.
The case study later in this article indicates the nature of the clinical problem confronting the GP managing a patient with cardiac failure with concurrent comorbidities. It demonstrates the difficulties experienced in managing patients with chronic and complex disease in community settings.
As this article points out, this can occur in a cost-effective manner only if a proper system of care is put in place that uses a framework such as the Wagner model [3] for chronic disease management, the six elements of which are outlined below:
• Health system organization of health care. This includes planned programs across a population with goals and targets that can be measured. It requires clinical, epidemiological, and policy expertise.
• Self-management support. Health professionals providing health education and empowering patients to monitor their symptoms and signs.
• Decision support. Ensuring that the latest evidencebased guidelines are incorporated into clinical practice while continuing to encourage clinical judgment in decision making.
• Delivery system design. Ensuring a team-based approach to the care of patients with chronic and complex disease while maintaining a pivotal role for the GP as the care coordinator.
• Clinical information systems. Use of IT support at the population level as well as at the clinic level to ensure that patient data are shared by all members of the care team and that local population data are made available to monitor progress.
• Community resources and policies. Developing partnerships with local hospitals, health services, and specialist clinics to support patient needs.
Prevalence of CHF
The exact prevalence of CHF is unknown and depends on the methods used to establish diagnosis.
Naturally, the use of echocardiography and B-type natriuretic peptide level in population screening will yield higher prevalence rates and will also identify those at risk so early therapeutic intervention may be implemented [4] .
Hospital data may be accurate but do not represent the true population prevalence. GP data may not represent undiagnosed cases, and the same applies to population surveys. In a systematic review of the literature by Sahle et al. [5] , the prevalence in Australia was estimated at 1%-2% of the population.
However, in developed countries in people older than 75 years the figure may be as high as 10%, rising to 13.6% in those aged 80-86 years. The prevalence in Australia is higher among indigenous people, women, and those living in rural communities, possibly related to aging for the latter two. In Australia approximately 350,000 people are being treated for CHF and there are approximately 45,000 admissions for CHF annually.
In the USA there are approximately 800,000 admissions a year for heart failure [2] ; any given patient may have several admissions a year. A population study in Rotterdam involving almost 8,000 participants older than 55 years found a higher prevalence in men, ranging from 0.9% in participants aged 55-64 years to 17.4% in those older than 85 years. The lifetime risk at age 55 years was 33% for men and 29% for women [6] .
A 2003 study in China [7] involving self-reporting by a random sample of 15,518 individuals aged 35-74 years revealed a prevalence of 0.9% in the general population, 0.7% for men and 1% for women. The prevalence increased with age (the Chinese population is now aging), and was greater in urban areas than in rural areas. Self-reporting may not reflect the true prevalence, and the prevalence rises sharply in those older than 75 years, so the true number in the whole population may well be greater than the 4 million estimated by the authors.
It is difficult to predict the prevalence going forward, However, the following factors will play a part [8] :
• Aging
• Increased prevalence of obesity, diabetes, hypertension, and ischemic heart disease 
Definition and classification
In simple terms, CHF occurs when cardiac output is insufficient to meet the body's needs at rest or with physical activity [9] . It is a clinical syndrome with symptoms of dyspnea and fatigue that can occur at rest or with effort, and is characterized by objective evidence of an underlying structural abnormality or cardiac dysfunction that impairs the ventricle from filling with or ejecting blood particularly during physical activity.
It may be further subdivided into systolic heart failure, where ejection is impaired, and diastolic heart failure, where cardiac filling is impaired. The former is known as heart failure with reduced ejection fraction, and the latter is also known as heart failure with preserved ejection fraction. The distinction may have some therapeutic and prognostic implications;
for example, beta blockers may not be used in heart failure with preserved ejection fraction. 
Causes of CHF
Coronary heart disease with past myocardial infarction is the commonest cause and accounts for more than half of new cases • Chest X-ray.
Diagnosis of CHF
• Electrocardiogram.
• Echocardiography. This is essential to confirm diagnosis, assess left ventricular function, and possibly identify a cause, including valvular abnormalities. It should be repeated every 2 years to monitor progress.
• Stress imaging with concurrent echocardiography study or nuclear study to assess perfusion.
• B-type natriuretic peptide level, which is sensitive in reflecting severity and hence prognosis. and in some cases reduction in all-cause mortality [10, 11] .
Principles of management
In some cases traditional Chinese medicine was part of the treatment.
Specific treatment
• General measures (self-management is vital in this condition, hence the importance of patient education and ensuring adherence to nonpharmacological as well as pharmacological treatment).
• Fluid restriction to usually less than 1.5 L/day.
• Daily weighing and notification of the clinic if there is a weight gain or decrease of more than 1.5 kg/day.
• Salt restriction to less than 2 g/day. No salt added to food or cooking.
• Regular low-level exercise.
• Management of cardiovascular risk factors, including weight control and smoking cessation.
• Vaccination against influenza annually and pneumococcal pneumonia every 5 years.
• Management of depression if present.
Pharmacological management
• Angiotensin-converting enzyme inhibitors (ACEIs) can prevent progression of disease and prolong survival [10] . Where ACEIs are not well tolerated, especially because of cough, then angiotensin II blockers may be used; however, they have not been shown to prolong survival [12] .
• Beta blockers in symptomatic patients in addition to
ACEIs may also prolong survival [9] .
• Diuretics maintain normal blood volume and provide symptomatic relief.
• Aldosterone antagonists (spironolactone) may be added to the previously mentioned medications.
• Digoxin in some patients especially for control of ventricular rate in atrial fibrillation.
• Pacemaker in patients with NYHA class III or IV disease.
• Implantable defibrillator in patients with CHF and severe systolic dysfunction of the left ventricle.
• Surgical procedures, including revascularization, insertion of devices, and cardiac transplant.
Management of the individual patient: The biopsychosocial approach
The following case study illustrates the challenges faced by the GP in whole patient care for a patient with CHF who like many in this category has multisystem disease and lives in difficult social circumstances [8] .
Case study
Mr. W is 76 years old and has a 15-year history of hypertension, ischemic heart disease, atrial fibrillation, obesity, type 2 diabetes, COPD, and osteoarthritis of his hips. He stopped smoking 12 years ago when he had four coronary artery bypass grafts. He lives with his 72-year-old wife, who also has type 2 diabetes, but is mainly concerned about her rheumatoid arthritis, which limits her activities. They have a son and daughter, who live in another province, and have two grandchildren, who they see only during holiday times. In the past 12 months Mr. W has had three hospital admissions for CHF.
He is dyspneic on walking 50 m, is worse in the cold, and also periodically gets angina while walking. He was assessed for further coronary revascularization or stents but was found on angiogram to have diffuse small vessel disease not suitable for intervention.
Clinical Examination Findings
• Pulse 68 and irregular(atrial fibrillation)
• Blood pressure 110/70 mm Hg • The case study of Mr. W illustrates the important role played by the GP in managing patients with NYHA class III or IV CHF as well as concurrent multimorbidity using a biopsychosocial approach.
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